MAPT and Alzheimer disease: In this study, the oral administration of the extract (6.7 mg/mL vs. 20 mg/mL) to 9-month-old female 3xTg AD mice for 3 months reduced both Aβ accumulation and tau hyper-phosphorylation (Thr181) to within a comparable range in the cortex and hippocampus.